Objective: To optimize sensitivity and disease specificity of a myelin oligodendrocyte glycoprotein (MOG) antibody assay.
similar methods, [12] [13] [14] [15] [16] [17] [18] but serologic findings and different experimental approaches suggested that MOG-Abs may be pathogenic. [19] [20] [21] [22] [23] More-specific assays using soluble, tetramerized extracellular domain of native MOG identified Abs in a subset of patients with acute disseminated encephalomyelitis (ADEM) but rarely in adult-onset MS cases, now suggesting that the test could be of relevance for discriminating MS from other demyelinating syndromes. 24 This was confirmed by cell-based assay (CBA) that also used a truncated MOG, in which MOGAbs were found in patients with aquaporin-4 (AQP4)-seronegative NMO but not those with MS. 25, 26 CBA using full-length human MOG (FL-MOG) appears to be more sensitive, and a clinical phenotype of ADEM and AQP4-seronegative NMO spectrum disorder (NMOSD), often optic neuritis (ON), is emerging. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] However, positivity in healthy individuals and patients with MS, even at relatively high serum dilutions (up to 1:640), affects its clinical use.
Here we confirm that C-terminal truncation of the MOG antigen reduces assay sensitivity and that many of the low positive Abs found to bind to FL-MOG result from crossreactivity of the anti-human IgG secondary antibody with IgM Abs. Using IgG1-specific secondary antibody allows use of lower serum dilutions with FL-MOG, with improved specificity for patients with ON, transverse myelitis (TM), AQP4-Ab-negative NMO, or ADEM.
METHODS Patients. Consecutive serum samples from 1,109 individuals sent for routine AQP4-Ab testing over 3 months were studied. Samples are sent to Oxford via clinical immunology laboratories with very limited or no clinical information. Sera from 118 of the 180 FL-MOG-positive samples were used to assess different secondary Abs, and 15/180 FL-MOG-seropositive samples were used for flow cytometry (a flow diagram of which samples were tested on the different assays is shown in figure 1 ). To assess the clinical relevance, a brief anonymized questionnaire was sent after the analyses to 48 identifiable referring clinicians requesting patient diagnosis, treatment responses, and relapses, if any. Controls were sera from previously archived cohorts. To validate the results, 2 other cohorts were screened. Patients seen at the National NMO Specialised Services who had already been tested for AQP4-Abs were tested for MOG-IgG1-Abs. After testing was completed, the diagnoses and follow-up times from the seropositive patients were obtained from a database. A further cohort of 101 Japanese patients with a range of demyelinating diagnoses (see Results) followed by or referred to Tohoku University Hospital and who had been previously tested for AQP4-Abs were tested for MOG-IgG1-Abs. All assays were carried out blinded to the clinical diagnoses.
Ethics. Ethics have been approved for the study of any patients whose samples have been referred to the Neuroimmunology laboratory in Oxford for diagnostic testing (Oxfordshire REC A; 07/Q1604/28 Immune factors in neurological disease). Since January 2010, data on all patients seen within the Oxford clinical NMO service have been entered prospectively into a clinical database and patient serum samples have been routinely tested for AQP4-Abs and MOG-Abs. The ethics committee of Tohoku University Graduate School of Medicine approved this study, and all participants provided written informed consent.
Constructs. The cloning of M23 isoform of human AQP4 has been described previously.
7 FL-MOG was cloned into pIRES2-DsRed2 using the forward primer (59-39): gatcctcgagccaccatggcaagcttatcaagaccctctctg and the reverse primer (59-39): gatccccgggtcagaagggatttcgtagctcttcaagg. A C-terminal-truncated MOG construct was created from the full-length construct by insertion of a stop codon after Gly155 and excision of the remainder of the C-terminus. The 2 forms differ only in the intracytoplasmic domain ( figure 2A ).
Cell-based assays. HEK293T cells, polyethylenimine (PEI) transfected with human M23-AQP4, FL-MOG, or Cterminal-truncated human MOG (short-length MOG; SL-MOG) were used as the substrate for live CBAs, which were performed as described elsewhere. [7] [8] [9] Patient sera were tested at 1:20 dilution. The Alexa Fluor 488 goat anti-human IgG (H 1 L) from Invitrogen (A1013, Carlsbad, CA) was used at 1:750 dilution. A semiquantitative scoring system was used: 0, no binding; 1, low-level binding; 2-4, increasing level of specific binding. Flow diagram of the assays and the samples that were evaluated A total of 1,109 samples were initially screened at a serum dilution of 1:20 for antibodies to aquaporin-4 (AQP4), short-length MOG (SL-MOG), and full-length human MOG (FL-MOG). Different secondary antibodies were then evaluated on FL-MOG-positive serum samples by FL-MOG cell-based assay (CBA) or flow cytometry. When the assay was established, 2 patient cohorts with clinical diagnoses from Oxford, UK and Sendai, Japan were used to calculate assay metrics.
Samples scoring .1 were considered positive. The average of 2 individual's scores is plotted (M.W., P.W. Primary research question. Does this MOG assay using an anti-human IgG1-specific secondary antibody identify a subgroup of AQP4-antibody-seronegative patients with a non-MS CNS demyelinating disease? This study provides Class II evidence that the presence of serum IgG1-Abs specific for MOG can distinguish AQP4-Abnegative patients with non-MS CNS demyelinating diseases from those with MS. The Japanese patients were used to calculate the assay metrics: 6 of 25 AQP4-Ab-negative patients with non-MS demyelinating diseases were MOG-IgG1 positive, for a sensitivity of 24% (95% confidence interval [CI] 9%-45%), and 0 of 27 patients with MS were MOG-IgG1 positive, for a specificity of 100% (95% CI 88%-100%).
RESULTS Out of 1,109 samples sent for diagnostic testing for AQP4-Abs, 40 sera were positive at 1:20 dilution. The SL-MOG assay detected Abs in 21 patients, including 1 (low positive) who was strongly positive for AQP4 (figure 2, B and C). However, the FL-MOG assays detected antibodies in 180 sera (16% of the test cohort), and 10 of these sera were also positive for AQP4-Abs (figure 2D). Positive results for FL-MOG were also found in 42/88 sera from patients with epilepsy (48%, figure 2B ).
Control groups and 118/180 FL-MOG-positive sera that were available were retested by CBA using either anti-IgG1 or anti-IgM class-specific secondary Abs (figure 3). With anti-IgM, 101/118 test sera, 7/10 healthy individuals, and 11/17 patients with MS were positive. The secondary antibody alone did not bind to FL-MOG-transfected HEK cells, and the control sera were negative on AQP4-transfected cells. With anti-IgG1, by contrast, only 65 of 118 sera had scores of greater than 1, and negative results were found in 49 patients with MS, 13 healthy sera, and 14 AQP4-Abpositive controls (figure 3C). figure 3D ). IgG in healthy control sera bound to FL-MOG-transfected cells when compared to the untransfected control cells in the same test sample when using anti-human IgG (H 1 L) or anti-human IgM secondary Abs, but not with the anti-human IgG1 secondary antibody ( figure 3D, horizontal arrows) . The majority of patients in each group substantially improved (13/17 IgG1 group vs 7/13 IgM only), and relapses were found in both groups (5/16 IgG1 and 6/12 IgM only).
Confirmatory cohorts. AQP4-seropositive NMOSD patients (37 NMO, 11 TM, 33 ON) seen by the Oxford NMO service were negative for MOG-IgG1-Abs; however, 23 AQP4-seronegative patients (8 NMO, 1 TM, 9 ON, 1 ON 1 TM, 4 ADEM) were MOG-IgG1 positive ( figure 4A, table 2 (table 2) .
DISCUSSION MOG-Abs have been detected using different methods, which affects the patient groups that are identified as seropositive. Initially, using peptide Western blots or ELISAs, patients with MS or viral or bacterial encephalitis were identified as MOG seropositive. More recently, the extracellular domain of native MOG has been used in immunoprecipitation assays in which the majority of patients with MS were seronegative but one-third of patients with ADEM were seropositive. The advent of the CBA enabled native human MOG to be expressed on the cell surface as a target for these Abs. Unfortunately, sera from many healthy individuals diluted 1:20 were seropositive using this assay; therefore, a "high-titer" serum cutoff of 1:160 is used to differentiate patient cohorts from healthy individuals. A few patients with MS, AQP4-seropositive patients, and healthy controls are still positive using this "high-titer" cutoff. 30 We confirm the lack of disease specificity of the MOG CBA at 1:20: 16% of sera sent for AQP4 Figure 4 Confirmatory cohorts to assess MOG-IgG1 assay testing and nearly 50% of patients with epilepsy were MOG positive. Similar positivity is seen in healthy control sera (data not shown). The secondary antibody IgG (H 1 L) binds to more than the IgG antibody class, which appears to affect the MOG CBA more than CBAs in which other targets are expressed (e.g., AQP4, GlyR). When examined by flow cytometry, the "low-level" binding of healthy control sera visualized by CBA is replicated by a specific shift in the MOG-transfected cells when compared to the untransfected or poorly transfected cells. Two advantages of this quantitative system are that the background binding can be quantified and a cutoff can be generated based on healthy sera. Using 6 SDs above the mean of a group of healthy control sera, the IgG (H 1 L) antibody gave a cutoff of 470, with the top of the assay 10 times this cutoff value (data not shown). Using the same control and test samples, the anti-human IgM secondary antibody gave a cutoff of 270, with the top of the assay only 3 times the cutoff and with very few positive samples, whereas the antihuman IgG1 antibody cutoff was just 2.5 and the top of the assay was 220 times this cutoff. The specificity of the MOG-IgG1 assay was confirmed by CBA in which 49 patients with MS, 13 healthy control sera, and 14 AQP4-seropositive serum samples were all negative at a dilution of 1:20, whereas 65 of the 118 samples that were positive using IgG (H 1 L) secondary antibody remained positive using the IgG1-specific antibody. None of the MOG-IgG1-positive patients with an available clinical diagnosis had MS, suggesting that this assay may be valuable to help distinguish patients with MS from those with ADEM or AQP4-Ab-negative NMOSD. Furthermore, 60/65 (92%) IgG1-positive samples had IgG (H 1 L) endpoint titers $1:200, indicating that the IgG1 assay identifies not only the patients above cutoff with the anti-IgG (H 1 L) but also disease-relevant Abs that fall below this cutoff. These findings are consistent with a previous report that high-titer MOG-Abs were exclusively of the IgG1 isotype. 30, 36, 38 Detection of IgM by CBA at a serum dilution of 1:20 did not distinguish different patient groups from healthy controls, limiting its diagnostic use. The flow cytometry data show that something in healthy and patient sera binds to the surface of MOGtransfected cells at low levels and is detected by anti-human IgG (H 1 L) or IgM antibodies. This is consistent with other studies reporting high levels of MOG-IgM-Abs using immunoblot or ELISA 1, 18, 39 and might be explained by the observation that MOG binds to components of the immune system such as C1q or DC-SIGN. 40, 41 The SL-MOG assay was previously shown to be negative in patients with MS and healthy controls, 26, 27 but here it only identified 32.3% of the IgG1 FL-MOG-Abs-positive samples (see table 1 ). As the extracellular domains are identical in the 2 constructs, the differences in assay sensitivity may be due to expression level on the surface, glycosylation, or ability to multimerize. Two of the 21 SL-MOG-positive patients were IgM positive only. The low sensitivity of the SL-MOG assay limits its use in clinical practice.
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